CA9 and glioblastoma: We next validated our in silico findings at the protein level using flow cytometry analysis to evaluate cell surface CA9 expression in a cohort of our patient-derived GBM BTIC lines as well as in normal brain cell lines [Normal Human Astrocyte (NHA) and Neural Stem Cells (NSC)].